ML
MRNA icon

McAdam LLC’s Moderna MRNA Stock Holding History

McAdam LLC’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,768
Closed -$489K – 373
2024
Q4 		$489K Buy
11,768
+562
+5% +$26.9K 0.03% 207
2024
Q3 		$749K Buy
11,206
+131
+1% +$12K 0.04% 155
2024
Q2 		$1.32M Buy
11,075
+117
+1% +$14.8K 0.08% 103
2024
Q1 		$1.17M Sell
10,958
-39
-0.4% -$3.93K 0.07% 107
2023
Q4 		$1.09M Buy
10,997
+2,529
+30% +$213K 0.08% 102
2023
Q3 		$875K Buy
8,468
+562
+7% +$62.7K 0.07% 117
2023
Q2 		$961K Buy
7,906
+1,092
+16% +$146K 0.08% 112
2023
Q1 		$1.05M Buy
6,814
+3,094
+83% +$510K 0.09% 108
2022
Q4 		$945K Sell
3,720
-1,399
-27% -$229K 0.09% 79
2022
Q3 		$605K Buy
5,119
+754
+17% +$114K 0.07% 120
2022
Q2 		$624K Buy
4,365
+159
+4% +$22.7K 0.07% 122
2022
Q1 		$725K Buy
4,206
+486
+13% +$81.8K 0.07% 94
2021
Q4 		$945K Buy
3,720
+1,336
+56% +$391K 0.09% 79
2021
Q3 		$918K Sell
2,384
-22
-0.9% -$8.11K 0.1% 76
2021
Q2 		$832K Buy
2,406
+106
+5% +$18.9K 0.09% 76
2021
Q1 		$301K Buy
+2,300
New +$333K 0.04% 120

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

McAdam LLC's MRNA Position: Q1 2025 in Review

McAdam LLC sold out of Moderna (MRNA) in Q1 2025, closing a stake of 11,768 shares — an estimated $489K sold.

McAdam LLC first reported a position in MRNA in Q1 2021 and held it in 16 quarters. The position peaked at $1.32M in Q2 2024. 694 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

  • McAdam LLC reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
  • McAdam LLC sold 11,768 Moderna shares in Q1 2025, an estimated $489K.
  • McAdam LLC first reported a position in Moderna in Q1 2021 and held it in 16 quarters.
  • McAdam LLC's Moderna position peaked at $1.32M in Q2 2024.
  • 694 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on McAdam LLC's 13F filing for Q1 2025, filed 21 May 2025.